Clinical Research And Innovation | SightMD Skip to main content

Research

Clinical Research at SightMD

One of the most exciting aspects of medicine is continuous innovation, scientific exploration, and research into how we can provide enhanced care for our patients. The field of ophthalmology has been on the forefront and recipient of revolutionizing technology, novel medications, premium devices, and innovative surgical techniques. Individually or combined, these advancements have provided patients with better vision and improved treatment options.

At SightMD we are continuously coupling efforts with top-tiered patient-centric industry-leading companies to bring the newest techniques, technologies, and medications to our patients through our Department of Clinical Research. Lead by Dr. Alanna Nattis, she has designed, developed, and exclusively accessed investigational treatment studies for wide-ranging ophthalmic conditions such as severe dry eye, glaucoma, refractive and cataract surgery, and retinal pathologies. Having direct access to FDA clinical trials uniquely provides SightMD with state-of-the-art care for our current and future patients.

Ongoing/Currently Enrolling Research Studies

We are currently recruiting for several active clinical trials. Please contact us for more information!

Evaluation of medication-releasing intraocular implant to treat open angle glaucoma and ocular hypertension.

Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP 0.5%

  • Principal Investigator (PI): Alanna Nattis, DO
  • Sub-Investigators (Sub-I’s): Richard Nattis MD, Raju Sarwal MD
  • Research Coordinator: Kathy Lemier, Sub-coordinator Mary Iaconis
  • Current patient enrollment: 18
  • Stage of Recruitment: Closed, data being processed
  • Trial type: Phase 3 FDA

In-depth evaluation using high-resolution corneal imaging during and after treatment for patients with neurotrophic keratitis treated with Recombinant Human Nerve Growth Factor (Oxervate)

Using OCT to measure regeneration of the cornea during/after treatment of neurotrophic keratitis with Oxervate

  • PI: Brad Kligman MD
  • Research Coordinator: Monique Murray
  • Current patient enrollment: 3
  • Stage of Recruitment: Open
  • Trial type: IIT

Eye exams provided to patients undergoing investigational research for novel chemotherapeutics/therapeutic regimens across the greater NYC area and Long Island

PI: several physicians across SightMD locations
Stage of Recruitment: Open

Designed to gather data to further understand genetic risk factors associated with AMD

  • PI: Edward Marcus, MD (SMD NY, NJ, PA, CT locations to enroll as well)
  • Research Coordinator: Uzma Siddiqui
  • Stage of Recruitment: Open
  • Trial Type: Pilot/Epidemiological

Evaluation of patient and provider perceptions and knowledge regarding diagnosis and treatment of demodex blepharitis in a real-world setting

  • PI: Alanna Nattis, DO
  • Sub-I: Eric Rosenberg, DO
  • Research Coordinator: Kathy Lemier
  • Stage of Recruitment: Open
  • Trial type: Observational post-market

A Real World Evidence (RWE) Long-Term Follow-Up Study to Assess Outcomes of Alcon Monofocal Intraocular Lenses

Evaluation in a long-term follow up time frame of the AcrySof single-piece and AcrySof multi-piece monofocal intraocular lenses

  • PI: Alanna Nattis, DO
  • Sub-I: Eric Rosenberg, DO
  • Research Coordinator: Kathy Lemier
  • Stage of Recruitment: Open
  • Trial Type: Phase 4 post-market

Long-term evaluation of safety and performance of Clareon Presbyopia Correcting IOLs – PMCF Study of Clareon Vivity & Clareon PanOptix

Long-term evaluation of patients post-bilateral implantation of Clareon Panoptix and/or Vivity intraocular lenses

  • PI: Alanna Nattis, DO
  • Sub-I: Eric Rosenberg, DO
  • Research Coordinator: Kathy Lemier
  • Stage of Recruitment: Open
  • Trial type: Phase 4, post-market

Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of POS (0.75% Phentolamine Ophthalmic Solution) in Subjects Who Have Previously Had Keratorefractive Surgery and Have Decreased Visual Acuity Under Mesopic Conditions

Evaluation of miotic eye drop on improvement in visual acuity and visual disturbances in patients who are post-LASIK/refractive surgery

  • PI: Jeffrey Martin, MD
  • Research Coordinator: Kelly Killoran
  • Stage of Recruitment: Open
  • Trial Type: Phase 3

Soon-to-be-Enrolling Studies

We will be looking open up the following clinical trials soon. Please contact us for more information!

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Patients with Geographic Atrophy Secondary to Age Related Macular Degeneration

Evaluation of subcutaneous medication on geographic atrophy in dry AMD

  • PI: Ed Marcus MD
  • Sub-I: Norman Saffra MD, Sabah Shah MD
  • Research Coordinator: Uzma Siddiqui
  • Trial type: Phase 3

Intraocular Pressure, Pachymetry & Keratometry Assessment Utilizing a Novel Non-invasive Device vs. Standard-of-Care Diagnostics

Comparison of a 4:1 novel device (TRK-3) on measuring IOP, pachymetry, keratometry and autorefraction compared to standard of care devices

  • PI: Alanna Nattis, DO
  • Sub-I: Eric Rosenberg, DO, Richard Nattis MD
  • Research Coordinator: Kathy Lemier
  • Sub-coordinator: Nathaly Vasquez
  • Trial type: Phase 3

Sign up for our newsletter

Stay up to date on the latest news, promotions, and research topics from across SightMD.

Subscribe Now